<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Oct. 10, 2019 (HealthDay News) — A class of diabetes drugs, called sodium-glucose co-transporter-2 (SGLT2) inhibitors, protect against kidney disease in patients with type 2 diabetes, according to a review published online Sept. 5 in The Lancet Diabetes & Endocrinology<\/i>.<\/p>\n
Brendon L. Neuen, M.B.B.S., from the University of New South Wales in Sydney, and colleagues conducted a systematic literature review to identify randomized, controlled trials of SGLT2 inhibitors that reported effects on major kidney outcomes in people with type 2 diabetes.<\/p>\n
The researchers identified four studies that assessed three SGLT2 inhibitors: empagliflozin, canagliflozin, and dapagliflozin. Among 38,723 participants, the researchers found that 252 patients required dialysis, transplantation, or died of kidney disease; 335 developed end-stage kidney disease; and 943 had acute kidney injury. There was a substantial reduction in the risk of dialysis, transplantation, or death due to kidney disease (relative risk, 0.67) with SGLT2 inhibitors. There was also a reduction in end-stage kidney disease (relative risk, 0.65) and acute kidney injury (relative risk, 0.75) with SGLT2 inhibitors. A benefit was seen for all estimated glomerular filtration rate and albuminuria subgroups.<\/p>\n
“These data provide substantive evidence supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n